Publications by authors named "J Zoeller"
Article Synopsis
- Germline BRCA1 mutation carriers have a high breast cancer risk, but the reasons for this increased risk are not fully understood.
- Researchers used a genetically engineered mouse model to show that the early onset of tumors in BRCA1 heterozygous mice can't be explained by the traditional "two-hit" hypothesis alone.
- Advanced techniques like single-cell RNA sequencing revealed distinct chromatin alterations in normal Brca1 heterozygous cells, hinting at epigenetic changes that might promote cancer, with specific transcription factors identified as key players in tumor development.
Restricting amino acids from tumors is an emerging therapeutic strategy with significant promise. While typically considered an intracellular antioxidant with tumor-promoting capabilities, glutathione (GSH) is a tripeptide of cysteine, glutamate, and glycine that can be catabolized, yielding amino acids. The extent to which GSH-derived amino acids are essential to cancers is unclear.
View Article and Find Full Text PDFTriple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived. Thus, there is an urgent need to develop more effective treatments.
View Article and Find Full Text PDFArticle Synopsis
- MYC is a critical driver of cancer that enhances gene expression and increases RNA production, contributing to tumor growth and survival.
- The study reveals that MYC triggers RNA degradation, leading to toxic byproducts that cause cancer cell death, indicating a new mechanism for targeting MYC-driven cancers.
- Therapeutic strategies that intensify the breakdown of RNA could serve as effective treatments for aggressive cancers like triple-negative breast cancer (TNBC) that rely on MYC.